This is supported by the fact that, in clinical practice, the use of IL-17 inhibitors in the treatment of psoriasis can lead to AD and, conversely, the use of IL-4/13 inhibitors in the treatment of AD can lead to psoriasis-like skin rashes. Here, IL4 is linked to psoriasis.